Atara Biotherapeutics (ATRA) Stock Rating Upgraded by BidaskClub
BidaskClub upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a hold rating to a buy rating in a research report sent to investors on Thursday.
A number of other equities research analysts also recently commented on the company. Canaccord Genuity reiterated a buy rating on shares of Atara Biotherapeutics in a report on Thursday, November 9th. Jefferies Group reiterated a buy rating and issued a $30.00 price objective on shares of Atara Biotherapeutics in a report on Thursday, October 5th. Citigroup upgraded Atara Biotherapeutics from a sell rating to a neutral rating and set a $18.00 price objective for the company in a report on Wednesday, January 3rd. Goldman Sachs Group reiterated a neutral rating and issued a $20.00 price objective on shares of Atara Biotherapeutics in a report on Friday, October 6th. Finally, ValuEngine upgraded Atara Biotherapeutics from a sell rating to a hold rating in a report on Friday, December 29th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Atara Biotherapeutics currently has an average rating of Buy and a consensus target price of $26.00.
Atara Biotherapeutics (NASDAQ ATRA) traded up $6.10 during mid-day trading on Thursday, hitting $28.25. The stock had a trading volume of 3,694,300 shares, compared to its average volume of 1,425,811. The company has a market capitalization of $864.33, a P/E ratio of -8.14 and a beta of 1.27. Atara Biotherapeutics has a 12 month low of $11.80 and a 12 month high of $30.40.
In other news, CEO Isaac E. Ciechanover sold 2,200 shares of the company’s stock in a transaction dated Friday, December 28th. The stock was sold at an average price of $15.15, for a total transaction of $33,330.00. Following the completion of the transaction, the chief executive officer now directly owns 743,675 shares of the company’s stock, valued at $11,266,676.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO John Mcgrath sold 37,000 shares of the company’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $24.35, for a total value of $900,950.00. Following the transaction, the chief financial officer now directly owns 93,154 shares of the company’s stock, valued at $2,268,299.90. The disclosure for this sale can be found here. Over the last three months, insiders sold 190,088 shares of company stock valued at $3,795,591. Insiders own 16.20% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Atara Biotherapeutics during the third quarter worth about $142,000. Russell Investments Group Ltd. acquired a new position in shares of Atara Biotherapeutics during the third quarter worth about $170,000. Voya Investment Management LLC boosted its position in shares of Atara Biotherapeutics by 16.2% during the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after buying an additional 1,651 shares during the period. State of Wisconsin Investment Board acquired a new position in shares of Atara Biotherapeutics during the second quarter worth about $252,000. Finally, The Manufacturers Life Insurance Company boosted its position in Atara Biotherapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 1,369 shares during the last quarter. 69.67% of the stock is owned by institutional investors.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Stock Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related stocks with our FREE daily email newsletter.